



DIASORIN S.P.A., THE ORDINARY SHAREHOLDERS' MEETING APPROVES THE 2010 STATUTORY FINANCIAL STATEMENTS AND THE DIVIDEND DISTRIBUTION.

Saluggia, April 28, 2011 – The Ordinary Shareholders' Meeting, convened under the chairmanship of Gustavo Denegri, was attended by shareholders representing 74.8% of the Company's share capital, who record the Group's results, reviewed and approved the statutory financial statements at December 31, 2010 and the dividend distribution motion.

In the course of the Shareholders' Meeting, Carlo Rosa, the Chief Executive Officer of DiaSorin S.p.A., presented and commented the Group's results: revenues grew to 404.5 million Euros, for a gain of 33.0% compared with 2009; margins continued to improve, causing EBIT to rise by 36.7% (+40,0% if net of nonrecurring items) to a total of 145.5 million Euros, equal to 36.0% of revenues (from 35.0% in 2009); net profit rose to 90.4 million Euros, for an increase of 29.1% compared with 2009.

Then the Shareholders' Meeting reviewed and approved the statutory financial statements at December 31, 2010 ended with revenues of 174.8 million Euros, or 21.6% more than in 2009, and a net profit of 69.9 million Euros, for an increase of 67.1% compared with 2009.

Lastly, the Shareholders' Meeting also approved a motion to distribute a dividend of 0.40 Euros per share outstanding at the coupon record date, with June 20, 2011 record date and June 23, 2011 payable date.



About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it

Contacts:

Investor Relations Director

Laura Villa

DiaSorin S.p.A.

laura.villa@Diasorin.it

+39 02 9647 4567

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02